Cancer Immunotherapy: Dana-Farber has licensed a large patent portfolio covering PD-1 and PD-L1 to multiple pharmaceutical companies
Acetylon Pharmaceuticals, a Dana-Farber start-up company, has launched Regenacy Pharmaceuticals, as Celgene Corporation acquires Acetylon
Myles Brown, MD, director of our Center for Functional Cancer Epigenetics, has been elected to The National Academy of Sciences
C4 Therapeutics, a successful Dana-Farber start-up company, is harnessing the innate power of the body to control the quality of proteins within cells
In the Robert and Renée Belfer Office for Dana-Farber Innovations (BODFI), our mission is to facilitate the transfer of research innovations from the laboratory to the clinic through timely commercialization, and to help Dana-Farber investigators create these innovations through collaborations and relationships with industry.
As a bridge between research and industry, BODFI is committed to building relationships with companies both large and small, with the investor community, and with entrepreneurs. Our goal is to create solutions.
At BODFI, we will: Work with you to license Dana-Farber technologies Facilitate your interactions with Dana-Farber's researchers, research centers, and core facilities Create novel collaboration structures to accommodate your evolving needs Coordinate with you to start new companies based on Dana-Farber innovations Expedite all necessary confidentiality, material transfer, or other agreements for the above
At BODFI, we will:
Collaborations and News PD-1 and PD-L1 patent portfolio Acetylon Pharmaceuticals Myles Brown, MD, elected to NAS C4 Therapeutics Dana-Farber and Astellas Dana-Farber and Eli Lilly
PD-1 and PD-L1 patent portfolio
Acetylon Pharmaceuticals
Myles Brown, MD, elected to NAS
C4 Therapeutics
Dana-Farber and Astellas
Dana-Farber and Eli Lilly
General: innovation@dfci.harvard.eduAcademic MTAs: jesse_medina@dfci.harvard.edu or mta@dfci.harvard.edu
Dana-Farber has established an open-source public repository of biopsy tissue collected from patients with leukemia and lymphoma, titled The Public Repository of Xenografts (PRoXe).
